CoChat

Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response

Smith, Melanie H., Bass, Anne R. · 2019 · Arthritis Care & Research
Cited by 92

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Objective: Musculoskeletal manifestations of immune‐related adverse events (ir AE s) after checkpoint inhibitor immunotherapy for cancer remain incompletely characterized and poorly understood. A recently published case series suggested that immunotherapy‐induced arthritis is an aggressive process requiring high‐dose corticosteroids. Methods: This was a retrospective chart review of all patients with musculoskeletal ir AE s first seen by one of the authors between 2014 and 2016. All patients had been treated for a malignancy with immune checkpoint inhibitors targeting PD‐1 (nivolumab, pembrolizumab), PD‐L1 (durvalumab), and/or CTLA‐4 (ipilimumab, tremelimumab) at Memorial Sloan Kettering Cancer Center. Results: We identified 10 patients with a mean ± SD age of 63.2 ± 9.7 years. Seven were treated with a combination of checkpoint inhibitors and 3 with nivolumab monotherapy. Four patients developed inflammatory polyarthritis, 4 oligoarthritis, and 2 tenosynovitis. Six were antinuclear antibody positive and 2 had anti–cyclic citrullinated peptide antibodies. Mean ± SD time from the first dose of immunotherapy until joint involvement was 6.3 ± 4.3 months. All 10 patients were treated with systemic corticosteroids, but 6 of 10 required ≤20 mg per day of prednisone. Five patients received steroid‐sparing agents. Mean ± SD time until resolution of joint symptoms after the last dose of immunotherapy was 9.2 ± 6.1 months. Conclusion: Musculoskeletal ir AE s can manifest as a rheumatoid arthritis–like polyarthritis, oligoarthritis, tenosynovitis, or polymyalgia rheumatica. Musculoskeletal symptoms can last more than a year, but they can generally be managed with low to moderate doses of corticosteroids.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acr.23467

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 92

Metadata

Authors
Smith, M. H., & Bass, A. R.
Venue
Arthritis Care & Research
Publisher
Wiley
Published
2018-08-23
Volume
71
Issue
3
Pages
362-366
ISSN
  • 0893-7524 (ISSN-L)
  • 2151-464X
  • 2151-4658
OpenAlex
W2767736444
Cited by
92
References
6
FWCI
5.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.